Impact of HIV infection and HAART on serum lipids in men

被引:458
作者
Riddler, SA
Smit, E
Cole, SR
Li, R
Chmiel, JS
Dobs, A
Palella, F
Visscher, B
Evans, R
Kingsley, LA
机构
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] SUNY Buffalo, Buffalo, NY 14260 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Northwestern Univ, Chicago, IL 60611 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 289卷 / 22期
关键词
D O I
10.1001/jama.289.22.2978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. Objective To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. Design, Setting, and Participants The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. Main Outcome Measures Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. Results Among the 50 men, notable declines in mean serum TC (-30 mg/dL [-0.78 mmol/L]) HDL-C (-12 mg/dL [-0.31 mmol/L]), and LDL-C values (-22 mg/dL [-0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], -1 to 41) and -1 mg/dL <LF>(-0.03 mmol/L) (95% Cl, -25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). Conclusions Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.
引用
收藏
页码:2978 / 2982
页数:5
相关论文
共 25 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[3]   Influence of protease inhibitor therapy on lipoprotein metabolism [J].
Berthold, HK ;
Parhofer, KG ;
Ritter, MM ;
Addo, M ;
Wasmuth, JC ;
Schliefer, K ;
Spengler, U ;
Rockstroh, JK .
JOURNAL OF INTERNAL MEDICINE, 1999, 246 (06) :567-575
[4]   Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens [J].
Bonnet, F ;
Savès, M ;
Droz, C ;
Peuchant, E ;
Chêne, G ;
Beylot, J ;
Morlat, P .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) :199-200
[5]   Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [J].
Bozzette, SA ;
Ake, CF ;
Tam, HK ;
Chang, SW ;
Louis, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :702-710
[6]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[7]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[8]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[9]  
Dong KL, 1999, J ACQ IMMUN DEF SYND, V21, P107
[10]  
FRIISMOLLER F, 2003, 10 C RETR OPP INF FE